August 22nd 2025
IMvigor011 showed significant improvement in survival outcomes with adjuvant atezolizumab in ctDNA-positive MIBC.
FDA Grants Pembrolizumab Priority Review for High-Risk Bladder Cancer
December 2nd 2019The FDA has granted a priority review designation to pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)–unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
Expert Discusses Genetic Predisposition to Prostate Cancer in Racially Diverse Patient Populations
October 31st 2019Genetic testing in cancer care is a relatively new element of the field, but some experts are looking to it to help prevent and understand prostate cancer in racially diverse populations.
Where New Updates in Genitourinary Cancer Continue to Come From
September 6th 2019The genitourinary cancer space has seen a lot of updates in the past 5-10 years, but where are they all coming from so suddenly? Oncology Nursing News spoke with Michael Lai, ARNP, a nurse practitioner at Seattle Cancer Care Alliance, about how the genitourinary cancer space has been able to have so many updates recently.
FDA Granted Enzalutamide Priority Review to Treat Metastatic Hormone-Sensitive Prostate Cancer
August 22nd 2019The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC), according to Astellas Pharma Inc. and Pfizer Inc., the codevelopers of the androgen receptor inhibitor.
Maintenance Pembrolizumab Improves Metastatic Urothelial Carcinoma Outcomes
June 30th 2019Switch maintenance treatment with pembrolizumab (Keytruda) improved progression-free survival (PFS) in patients with metastatic urothelial cancer who have stable disease following frontline platinum-based chemotherapy, according to results of a randomized phase II study that were presented at the 2019 ASCO Annual Meeting.
FDA Approves Bevacizumab Biosimilar for 5 Cancer Types
June 28th 2019The Food and Drug Administration approved bevacizumab-bvzr (Zirabev) – a biosimilar for bevacizumab (Avastin) for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.
Researchers Address Unmet Need in Bladder Cancer Detection
May 17th 2019Two new urine tests currently being investigated for bladder cancer detection and monitoring have demonstrated more than 90% sensitivity and specificity – highlighting the potential for addressing an unmet need among this patient population.
Expert Looks Ahead in Prostate Cancer Treatment
May 12th 2019When it comes to the treatment of patients with nonmetastatic castration-resistant prostate cancer (M0CRPC), 3 pivotal trials—SPARTAN, PROSPER, and most recently, ARAMIS—have demonstrated the safety and efficacy of second-generation targeted antiandrogens, said Richard (Rick) JaeBong Lee, MD, PhD.